Abstract Number: LB17 • ACR Convergence 2025
Circulating biomarkers for organ involvement in systemic lupus erythematosus: a series of systematic reviews and meta-analyses
Background/Purpose: Systemic lupus erythematosus (SLE) features heterogeneous clinical manifestations. The identification of biomarkers that facilitate initial disease recognition is a cornerstone of optimized clinical management.…Abstract Number: LB18 • ACR Convergence 2025
Transcriptomic Signatures of ANA+ and ANA- B Cells Reveal Shifts from Active Disease to Remission in Systemic Lupus Erythematosus
Background/Purpose: In systemic lupus erythematosus (SLE), IgG antibodies that target nuclear antigens (ANA) are pathogenic and part of the diagnostic criteria for SLE. Healthy individuals…Abstract Number: LB22 • ACR Convergence 2025
Early Evidence of Proof-of-Concept of an Albumin-DNASE1L3 Fusion Protein (NTR-441) for the Rapid Enzymatic Inactivation of NETs in SLE with DNASE1L3-Deficiency
Background/Purpose: Excessive formation and impaired clearance of Neutrophil Extracellular Traps (NETs) have been linked to autoimmune and inflammatory diseases, notably systemic lupus erythematosus (SLE). DNASE1-like…Abstract Number: LB01 • ACR Convergence 2025
Low-dose Interleukin-2 Therapy in Systemic Lupus Erythematosus: a double-blind, randomised, placebo-controlled, phase IIb trial
Background/Purpose: Low-dose Interleukin-2 (Ld-IL2) has shown therapeutic effect in autoimmune diseases, particularly systemic lupus erythematosus (SLE). Various doses from 0.33 to 3.0 million units of…Abstract Number: LB10 • ACR Convergence 2025
Four-Year Safety and Efficacy of Deucravacitinib in Systemic Lupus Erythematosus: Results From a Phase 2 Program
Background/Purpose: There is a substantial unmet need for effective, well-tolerated therapies for patients with SLE. Deucravacitinib is an oral, selective tyrosine kinase 2 (TYK2) inhibitor…Abstract Number: 0133 • ACR Convergence 2025
Differences in cardiovascular risk factor control between primary and systemic lupus erythematosus-related antiphospholipid syndrome in a multiethnic cohort of 1003 patients with antiphospholipid syndrome: the SUrvey of cardiovascular disease Risk Factors (SURF) in SLE and APS project
Background/Purpose: Cardiovascular disease (CVD) in antiphospholipid syndrome (APS) is driven by antiphospholipid antibody-mediated immunothrombotic mechanisms and traditional cardiovascular risk factors (CVRFs). Although the EULAR recommendations…Abstract Number: 0381 • ACR Convergence 2025
Improving Participation in The Lupus Foundation of America’s Research Accelerated by You (RAY) Patient Registry By Understanding Patient Preference in Communication Strategies
Background/Purpose: The purpose of Research Accelerated by You (RAY) is to amplify awareness about clinical research and trials and ensure lupus patient partnership in therapeutic…Abstract Number: 0838 • ACR Convergence 2025
Complete Renal Response and Long-Term, Progression-Free Survival in Adult Patients With Lupus Nephritis: A Retrospective Cohort Study in the United States
Background/Purpose: Complete renal response (CRR) and flare prevention, as early markers of long-term kidney survival, are important outcomes in lupus nephritis (LN) clinical trials.Methods: This…Abstract Number: 0604 • ACR Convergence 2025
Assessment of the Metabolic Score for Insulin Resistance (METS-IR) and Its Associated Factors in Patients with Systemic Lupus Erythematosus
Background/Purpose: The Metabolic Score for Insulin Resistance (METS-IR) is a recently developed index proposed as a predictor of cardiovascular (CV) events. In this study, we…Abstract Number: 0620 • ACR Convergence 2025
The usefulness of neutrophil-to-lymphocyte ratio as a biomarker to predict lupus flares in patients under remission
Background/Purpose: Remission in Systemic Lupus Erythematosus (SLE) is described by the Definition of Remission in SLE (DORIS), but it is hardly achieved in clinical practice,…Abstract Number: 0639 • ACR Convergence 2025
Kidney Transplantation In Lupus Nephritis. Multicenter Study Of 103 Patients
Background/Purpose: Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus (SLE) affecting to 40-60% of SLE. End-stage renal disease (ESRD) occurs in up…Abstract Number: 0663 • ACR Convergence 2025
iPSC-Derived Off-the-Shelf anti-CD19 CAR T cells Deliver Improved Clinical Outcomes in Lupus with Reduced or No Conditioning Chemotherapy
Background/Purpose: Anti-CD19 chimeric antigen receptor (CAR) T cell therapy shows promise in autoimmune disease. However, autologous CAR T-cell therapy is limited by prolonged pre- and…Abstract Number: 0934 • ACR Convergence 2025
The Use Of Preclinical Models To Understand Drivers Of Lupus Pathogenesis
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic, multisystem autoimmune disease with a prevalence of 1.4-15.13/100,000 adults globally. SLE is highly heterogenous and can involve…Abstract Number: 1009 • ACR Convergence 2025
Pregnancy Outcomes and Comorbidities Among Individuals with Systemic Lupus Erythematosus: A Nationwide Study Using Publicly Funded Health Insurance Claims Data
Background/Purpose: Individuals with SLE are at increased risk for pregnancy complications such as preeclampsia and preterm delivery. As SLE is commonly diagnosed and active during…Abstract Number: 1179 • ACR Convergence 2025
Efficacy and Safety of Ruxolitinib in Adult Patients With Refractory Connective Tissue Disease-Associated Macrophage Activation Syndrome
Background/Purpose: Macrophage activation syndrome (MAS) is a rare and life-threatening complication of connective tissue diseases (CTDs), with approximately 30% of cases being refractory to standard…
- 1
- 2
- 3
- …
- 181
- Next Page »